Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $61.18

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $61.18.

A number of equities analysts have commented on TEM shares. TD Cowen reissued a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Piper Sandler reduced their price objective on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Loop Capital lowered their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, Bank of America raised their price target on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $48.04 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The firm’s 50-day moving average price is $56.07 and its 200 day moving average price is $51.45.

Insider Buying and Selling at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the sale, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jennifer A. Doudna sold 1,320 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the sale, the director now owns 36,011 shares in the company, valued at approximately $3,240,990. This trade represents a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,598,969 shares of company stock worth $317,194,162 in the last ninety days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new position in shares of Tempus AI during the 4th quarter worth approximately $108,000. Voloridge Investment Management LLC acquired a new position in Tempus AI during the fourth quarter worth $11,826,000. Two Sigma Advisers LP acquired a new position in Tempus AI during the fourth quarter worth $625,000. ProShare Advisors LLC purchased a new position in shares of Tempus AI during the fourth quarter worth $244,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at $1,034,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.